Compared to the tumor size in the control mice, the significant difference in tumor growth between the PTX-treated mice and PTX + ANF-treated mice further confirmed that decreasing the expression or activity of CYP1B1 can potentiate the anticancer abilities of PTX, provided that both treatments are concurrent (P<0.01). Here, CYP1B1 is linked to neoplasm.